{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-230409","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2025-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.005181+00:00","generated_at":"2026-05-17T04:46:29.522706+00:00","sec_items":["1.01","3.02","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Ovid reports positive Phase 1 OV329 results and raises $175M in PIPE financing","bullets":["OV329 Phase 1: 53% inhibition increase on LICI biomarker (p=0.0001) at 5mg, exceeding vigabatrin (~35%); mild AEs only.","No ophthalmic changes observed; plan Phase 2a in drug-resistant focal onset seizures Q2 2026.","PIPE financing of up to $175.1M (initial $80.8M) from sale of Series B Preferred and warrants at $1.40/share.","Warrants exercisable after stockholder approval; proceeds for R&D and working capital; closing Oct 6, 2025.","KCC2 program updates: OV350 topline PK data Q4 2025; OV4071 IND filing Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-230409","json":"https://secwatch.observer/filing/0001193125-25-230409.json","markdown":"https://secwatch.observer/filing/0001193125-25-230409.md","text":"https://secwatch.observer/filing/0001193125-25-230409.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000119312525230409/0001193125-25-230409-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000119312525230409/d45212d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:46:29.522706+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"13bcc1852c15b38a293fbdf7b4ebbcad0fa3144a","claim":"Ovid Therapeutics Inc. issued to purchase 38,481,325 shares of Common Stock of warrant to the Investors (including the Chief Executive Officer) for $1,400.00 per Security.","evidence_excerpt":"purchase) and a Series B Warrant to purchase 500 shares of Common Stock and/or Pre-Funded Warrants (together, a “Security”). The Securities will be sold at a purchase price of $1,400.00 per Security to the Investors, which includes the Company’s Chief Executive Officer. The Warrants will each have an exercise price of $1.40 per share. The PIPE financing is","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000119312525230409/0001193125-25-230409-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"to purchase 38,481,325 shares of Common Stock"},{"label":"Purchaser","value":"the Investors (including the Chief Executive Officer)"},{"label":"Consideration","value":"$1,400.00 per Security"}],"fact_type":"equity_issuance"},{"claim_id":"914d2a30e8674d3cfcd67b1a299db249178fba5f","claim":"Ovid Therapeutics Inc. issued 57,722 shares of preferred stock to the Investors (including the Chief Executive Officer) for $1,400.00 per Security.","evidence_excerpt":"purchase) and a Series B Warrant to purchase 500 shares of Common Stock and/or Pre-Funded Warrants (together, a “Security”). The Securities will be sold at a purchase price of $1,400.00 per Security to the Investors, which includes the Company’s Chief Executive Officer. The Warrants will each have an exercise price of $1.40 per share. The PIPE financing is","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000119312525230409/0001193125-25-230409-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"preferred stock"},{"label":"Shares","value":"57,722 shares"},{"label":"Purchaser","value":"the Investors (including the Chief Executive Officer)"},{"label":"Consideration","value":"$1,400.00 per Security"}],"fact_type":"equity_issuance"},{"claim_id":"c2fabdcd5fb286da5f6fc605f7c7f2b9f1d01023","claim":"Ovid Therapeutics Inc. issued to purchase 28,861,000 shares of Common Stock of warrant to the Investors (including the Chief Executive Officer) for $1,400.00 per Security.","evidence_excerpt":"purchase) and a Series B Warrant to purchase 500 shares of Common Stock and/or Pre-Funded Warrants (together, a “Security”). The Securities will be sold at a purchase price of $1,400.00 per Security to the Investors, which includes the Company’s Chief Executive Officer. The Warrants will each have an exercise price of $1.40 per share. The PIPE financing is","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000119312525230409/0001193125-25-230409-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"to purchase 28,861,000 shares of Common Stock"},{"label":"Purchaser","value":"the Investors (including the Chief Executive Officer)"},{"label":"Consideration","value":"$1,400.00 per Security"}],"fact_type":"equity_issuance"},{"claim_id":"bb5d7f34e251171b37d2ea105a8ce5da35d41321","claim":"Ovid Therapeutics Inc.: Filed Certificate of Designation establishing Series B Convertible Preferred Stock designating 57,722 shares of preferred stock (effective 2025-10-03).","evidence_excerpt":"On October 3, 2025, the Company filed the Certificate of Designation with the Delaware Secretary of State designating 57,722 shares of its authorized and unissued preferred stock as Series B Preferred Stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000119312525230409/0001193125-25-230409-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-10-03"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}